Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) EBIT Margin (2016 - 2025)

BioCorRx (BICX) has disclosed EBIT Margin for 15 consecutive years, with 1333.2% as the latest value for Q4 2025.

  • Quarterly EBIT Margin changed N/A to 1333.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 702.97% through Dec 2025, up 6612684.0% year-over-year, with the annual reading at 606.04% for FY2025, 6622377.0% up from the prior year.
  • EBIT Margin hit 1333.2% in Q4 2025 for BioCorRx, down from 306.28% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 306.28% in Q3 2025 to a low of 33852.95% in Q2 2024.
  • Historically, EBIT Margin has averaged 8419.42% across 5 years, with a median of 5151.96% in 2022.
  • Biggest five-year swings in EBIT Margin: plummeted -2903044bps in 2024 and later surged 3305968bps in 2025.
  • Year by year, EBIT Margin stood at 9790.91% in 2021, then surged by 85bps to 1430.79% in 2022, then tumbled by -204bps to 4344.24% in 2023, then tumbled by -679bps to 33852.95% in 2024, then surged by 96bps to 1333.2% in 2025.
  • Business Quant data shows EBIT Margin for BICX at 1333.2% in Q4 2025, 306.28% in Q3 2025, and 793.28% in Q2 2025.